SCHEMBL2643968

SCHEMBL2643968

CC1(C)Cc2c(Oc3ccc(C(=N)NO)cc3)cc(C(=O)O)cc2O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.42
RXRA P19793 2/20 0.40
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 4/20 0.37
GAA P10253 4/20 0.37
HPGD P15428 3/20 0.37
CASP1 P29466 2/20 0.37
HSD17B10 Q99714 2/20 0.37
GLA P06280 2/20 0.37
CASP7 P55210 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
TTR P02766 2/20 0.36
FFAR4 Q5NUL3 1/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.33
NOD1 Q9Y239 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
LMNA P02545 2/20 0.32
MAPT P10636 2/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644137 0.86 GCK (0.44) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL2644007 0.86 GCK (0.47) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL2644082 0.86 GCK (0.53) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL642785 0.83 ALDH1A1 (0.46) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL9071970 0.82 GCK (0.40) GCK
SCHEMBL2644143 0.81 MAOB (0.43) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL2644394 0.81 GCK (0.42) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL643275 0.81 PTGS2 (0.41) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL643904 0.81 GCK (0.54) GCKRXRAALDH1A1KDM4EGAA
SCHEMBL2643898 0.81 GCK (0.52) GCKALDH1A1KDM4EGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885RXRA 2180/4885ALDH1A1 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.